Ocugen stock jumped another 6% in premarket trading

Tiger Newspress2021-11-02

Ocugen stock jumped another 6% in premarket trading after soaring more than 18% yesterday amid heightened interest in the stock from retail traders on social media.

According to SwaggyStocks, Ocugen was the fifth most mentioned stock on Reddit's r/wallstreetbets.

Traders also circulated a recent release from the Australian Government mentioning recognition of Bharat Biotech's COVAXIN. NOTE: Ocugen is a partner on COVAXIN.

Ocugen's average session volume is 21.45 million over a 100-day period.

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases.

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

szueyann
2021-11-02
szueyann
Like pls
- szueyann:
  ok
LaoLong
2021-11-02
LaoLong
All the way to moon bank
marcuslee
2021-11-02
marcuslee
Sure win
JeffRC
2021-11-02
JeffRC
Sky is the limit
- JANICELSJ:
  Ok
han1911
2021-11-02
han1911
To the moon
- Shhui:
  Yea
- Rontjk:
  Ok

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1125550592?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-11-02 20:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1125550592","market":"us","top_or_hot":-1,"title":"Ocugen stock jumped another 6% in premarket trading","media":"Tiger Newspress","content":"<p>Ocugen stock jumped another 6% in premarket trading&nbsp;after&nbsp;soaring more than 18% yesterday&nbsp;amid heightened interest in the stock from retail traders on social media.</p>\n<p><img src=\"https://static.tigerbbs.com/c79efec1c07b47773449a998fa009813\" tg-width=\"847\" tg-height=\"619\" referrerpolicy=\"no-referrer\"></p>\n<p>According to SwaggyStocks, Ocugen was the fifth most mentioned stock on Reddit's r/wallstreetbets.</p>\n<p>Traders also circulated a recent release from the Australian Government mentioning recognition of Bharat Biotech's COVAXIN. NOTE: Ocugen is a partner on COVAXIN.</p>\n<p>Ocugen's average session volume is 21.45 million over a 100-day period. </p>\n<p>Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen stock jumped another 6% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen stock jumped another 6% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n2021-11-02 20:50 北京时间&nbsp;&nbsp;&nbsp;<strong>Tiger Newspress</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ocugen stock jumped another 6% in premarket trading after soaring more than 18% yesterday amid heightened interest in the stock from retail traders on social media.\n\nAccording to SwaggyStocks, Ocugen ...</p>\n\n<a href=\"None\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OCGN","symbol_name":"Ocugen","start_time":0,"source_url":null,"article_id":"1125550592","we_media_id":"1079075236","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1125550592","pubTimestamp":1635857440,"sourceInfo":null,"weMediaInfo":{"media_name":"Tiger Newspress","introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"summary":"Ocugen stock jumped another 6% in premarket trading after soaring more than 18% yesterday amid heigh","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OCGN":"Ocugen"},"translate_title":"Ocugen的股票在盘前交易中又上涨了6%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCGN":0.9},"content_text":"Ocugen stock jumped another 6% in premarket trading after soaring more than 18% yesterday amid heightened interest in the stock from retail traders on social media.\n\nAccording to SwaggyStocks, Ocugen was the fifth most mentioned stock on Reddit's r/wallstreetbets.\nTraders also circulated a recent release from the Australian Government mentioning recognition of Bharat Biotech's COVAXIN. NOTE: Ocugen is a partner on COVAXIN.\nOcugen's average session volume is 21.45 million over a 100-day period. \nOcugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":841024214,"gmtCreate":1635864289435,"gmtModify":1635864289938,"author":{"id":"3573721781255613","authorId":"3573721781255613","name":"szueyann","avatar":"https://static.tigerbbs.com/cba9c6b1e785a9cf7301a7e6a2ff2354","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3573721781255613","authorIdStr":"3573721781255613"},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/841024214","repostId":1125550592,"repostType":4,"repost":{"id":"1125550592","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635857440,"share":"https://www.laohu8.com/m/news/1125550592?lang=&edition=full","pubTime":"2021-11-02 20:50","market":"us","language":"en","title":"Ocugen stock jumped another 6% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1125550592","media":"Tiger Newspress","summary":"Ocugen stock jumped another 6% in premarket trading after soaring more than 18% yesterday amid heigh","content":"<p>Ocugen stock jumped another 6% in premarket trading&nbsp;after&nbsp;soaring more than 18% yesterday&nbsp;amid heightened interest in the stock from retail traders on social media.</p>\n<p><img src=\"https://static.tigerbbs.com/c79efec1c07b47773449a998fa009813\" tg-width=\"847\" tg-height=\"619\" referrerpolicy=\"no-referrer\"></p>\n<p>According to SwaggyStocks, Ocugen was the fifth most mentioned stock on Reddit's r/wallstreetbets.</p>\n<p>Traders also circulated a recent release from the Australian Government mentioning recognition of Bharat Biotech's COVAXIN. NOTE: Ocugen is a partner on COVAXIN.</p>\n<p>Ocugen's average session volume is 21.45 million over a 100-day period. </p>\n<p>Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen stock jumped another 6% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen stock jumped another 6% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-02 20:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ocugen stock jumped another 6% in premarket trading&nbsp;after&nbsp;soaring more than 18% yesterday&nbsp;amid heightened interest in the stock from retail traders on social media.</p>\n<p><img src=\"https://static.tigerbbs.com/c79efec1c07b47773449a998fa009813\" tg-width=\"847\" tg-height=\"619\" referrerpolicy=\"no-referrer\"></p>\n<p>According to SwaggyStocks, Ocugen was the fifth most mentioned stock on Reddit's r/wallstreetbets.</p>\n<p>Traders also circulated a recent release from the Australian Government mentioning recognition of Bharat Biotech's COVAXIN. NOTE: Ocugen is a partner on COVAXIN.</p>\n<p>Ocugen's average session volume is 21.45 million over a 100-day period. </p>\n<p>Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125550592","content_text":"Ocugen stock jumped another 6% in premarket trading after soaring more than 18% yesterday amid heightened interest in the stock from retail traders on social media.\n\nAccording to SwaggyStocks, Ocugen was the fifth most mentioned stock on Reddit's r/wallstreetbets.\nTraders also circulated a recent release from the Australian Government mentioning recognition of Bharat Biotech's COVAXIN. NOTE: Ocugen is a partner on COVAXIN.\nOcugen's average session volume is 21.45 million over a 100-day period. \nOcugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6427072,"gmtCreate":1635864302309,"gmtModify":1635864302395,"authorId":3573721781255613,"author":{"id":3573721781255613,"idStr":"3573721781255613","authorId":3573721781255613,"name":"szueyann","avatar":"https://static.tigerbbs.com/cba9c6b1e785a9cf7301a7e6a2ff2354","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":841024214,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"CN"},{"id":843781580,"gmtCreate":1635858984742,"gmtModify":1635858984897,"author":{"id":"3573636627450479","authorId":"3573636627450479","name":"LaoLong","avatar":"https://static.tigerbbs.com/ff505ac2e3cd8ccdacd48735fcde94ce","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3573636627450479","authorIdStr":"3573636627450479"},"htmlText":"All the way to moon bank","listText":"All the way to moon bank","text":"All the way to moon bank","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/843781580","repostId":1125550592,"repostType":4,"repost":{"id":"1125550592","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635857440,"share":"https://www.laohu8.com/m/news/1125550592?lang=&edition=full","pubTime":"2021-11-02 20:50","market":"us","language":"en","title":"Ocugen stock jumped another 6% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1125550592","media":"Tiger Newspress","summary":"Ocugen stock jumped another 6% in premarket trading after soaring more than 18% yesterday amid heigh","content":"<p>Ocugen stock jumped another 6% in premarket trading&nbsp;after&nbsp;soaring more than 18% yesterday&nbsp;amid heightened interest in the stock from retail traders on social media.</p>\n<p><img src=\"https://static.tigerbbs.com/c79efec1c07b47773449a998fa009813\" tg-width=\"847\" tg-height=\"619\" referrerpolicy=\"no-referrer\"></p>\n<p>According to SwaggyStocks, Ocugen was the fifth most mentioned stock on Reddit's r/wallstreetbets.</p>\n<p>Traders also circulated a recent release from the Australian Government mentioning recognition of Bharat Biotech's COVAXIN. NOTE: Ocugen is a partner on COVAXIN.</p>\n<p>Ocugen's average session volume is 21.45 million over a 100-day period. </p>\n<p>Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen stock jumped another 6% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen stock jumped another 6% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-02 20:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ocugen stock jumped another 6% in premarket trading&nbsp;after&nbsp;soaring more than 18% yesterday&nbsp;amid heightened interest in the stock from retail traders on social media.</p>\n<p><img src=\"https://static.tigerbbs.com/c79efec1c07b47773449a998fa009813\" tg-width=\"847\" tg-height=\"619\" referrerpolicy=\"no-referrer\"></p>\n<p>According to SwaggyStocks, Ocugen was the fifth most mentioned stock on Reddit's r/wallstreetbets.</p>\n<p>Traders also circulated a recent release from the Australian Government mentioning recognition of Bharat Biotech's COVAXIN. NOTE: Ocugen is a partner on COVAXIN.</p>\n<p>Ocugen's average session volume is 21.45 million over a 100-day period. </p>\n<p>Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125550592","content_text":"Ocugen stock jumped another 6% in premarket trading after soaring more than 18% yesterday amid heightened interest in the stock from retail traders on social media.\n\nAccording to SwaggyStocks, Ocugen was the fifth most mentioned stock on Reddit's r/wallstreetbets.\nTraders also circulated a recent release from the Australian Government mentioning recognition of Bharat Biotech's COVAXIN. NOTE: Ocugen is a partner on COVAXIN.\nOcugen's average session volume is 21.45 million over a 100-day period. \nOcugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":843716689,"gmtCreate":1635858483012,"gmtModify":1635858483116,"author":{"id":"3576123430744303","authorId":"3576123430744303","name":"marcuslee","avatar":"https://static.tigerbbs.com/0f6baca028eb47f9f91370dc92958fcf","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3576123430744303","authorIdStr":"3576123430744303"},"htmlText":"Sure win","listText":"Sure win","text":"Sure win","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/843716689","repostId":1125550592,"repostType":2,"repost":{"id":"1125550592","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635857440,"share":"https://www.laohu8.com/m/news/1125550592?lang=&edition=full","pubTime":"2021-11-02 20:50","market":"us","language":"en","title":"Ocugen stock jumped another 6% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1125550592","media":"Tiger Newspress","summary":"Ocugen stock jumped another 6% in premarket trading after soaring more than 18% yesterday amid heigh","content":"<p>Ocugen stock jumped another 6% in premarket trading&nbsp;after&nbsp;soaring more than 18% yesterday&nbsp;amid heightened interest in the stock from retail traders on social media.</p>\n<p><img src=\"https://static.tigerbbs.com/c79efec1c07b47773449a998fa009813\" tg-width=\"847\" tg-height=\"619\" referrerpolicy=\"no-referrer\"></p>\n<p>According to SwaggyStocks, Ocugen was the fifth most mentioned stock on Reddit's r/wallstreetbets.</p>\n<p>Traders also circulated a recent release from the Australian Government mentioning recognition of Bharat Biotech's COVAXIN. NOTE: Ocugen is a partner on COVAXIN.</p>\n<p>Ocugen's average session volume is 21.45 million over a 100-day period. </p>\n<p>Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen stock jumped another 6% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen stock jumped another 6% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-02 20:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ocugen stock jumped another 6% in premarket trading&nbsp;after&nbsp;soaring more than 18% yesterday&nbsp;amid heightened interest in the stock from retail traders on social media.</p>\n<p><img src=\"https://static.tigerbbs.com/c79efec1c07b47773449a998fa009813\" tg-width=\"847\" tg-height=\"619\" referrerpolicy=\"no-referrer\"></p>\n<p>According to SwaggyStocks, Ocugen was the fifth most mentioned stock on Reddit's r/wallstreetbets.</p>\n<p>Traders also circulated a recent release from the Australian Government mentioning recognition of Bharat Biotech's COVAXIN. NOTE: Ocugen is a partner on COVAXIN.</p>\n<p>Ocugen's average session volume is 21.45 million over a 100-day period. </p>\n<p>Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125550592","content_text":"Ocugen stock jumped another 6% in premarket trading after soaring more than 18% yesterday amid heightened interest in the stock from retail traders on social media.\n\nAccording to SwaggyStocks, Ocugen was the fifth most mentioned stock on Reddit's r/wallstreetbets.\nTraders also circulated a recent release from the Australian Government mentioning recognition of Bharat Biotech's COVAXIN. NOTE: Ocugen is a partner on COVAXIN.\nOcugen's average session volume is 21.45 million over a 100-day period. \nOcugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":843733952,"gmtCreate":1635857536563,"gmtModify":1635857536673,"author":{"id":"3575901346969727","authorId":"3575901346969727","name":"JeffRC","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":7,"crmLevelSwitch":0,"idStr":"3575901346969727","authorIdStr":"3575901346969727"},"htmlText":"Sky is the limit","listText":"Sky is the limit","text":"Sky is the limit","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/843733952","repostId":1125550592,"repostType":2,"repost":{"id":"1125550592","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635857440,"share":"https://www.laohu8.com/m/news/1125550592?lang=&edition=full","pubTime":"2021-11-02 20:50","market":"us","language":"en","title":"Ocugen stock jumped another 6% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1125550592","media":"Tiger Newspress","summary":"Ocugen stock jumped another 6% in premarket trading after soaring more than 18% yesterday amid heigh","content":"<p>Ocugen stock jumped another 6% in premarket trading&nbsp;after&nbsp;soaring more than 18% yesterday&nbsp;amid heightened interest in the stock from retail traders on social media.</p>\n<p><img src=\"https://static.tigerbbs.com/c79efec1c07b47773449a998fa009813\" tg-width=\"847\" tg-height=\"619\" referrerpolicy=\"no-referrer\"></p>\n<p>According to SwaggyStocks, Ocugen was the fifth most mentioned stock on Reddit's r/wallstreetbets.</p>\n<p>Traders also circulated a recent release from the Australian Government mentioning recognition of Bharat Biotech's COVAXIN. NOTE: Ocugen is a partner on COVAXIN.</p>\n<p>Ocugen's average session volume is 21.45 million over a 100-day period. </p>\n<p>Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen stock jumped another 6% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen stock jumped another 6% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-02 20:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ocugen stock jumped another 6% in premarket trading&nbsp;after&nbsp;soaring more than 18% yesterday&nbsp;amid heightened interest in the stock from retail traders on social media.</p>\n<p><img src=\"https://static.tigerbbs.com/c79efec1c07b47773449a998fa009813\" tg-width=\"847\" tg-height=\"619\" referrerpolicy=\"no-referrer\"></p>\n<p>According to SwaggyStocks, Ocugen was the fifth most mentioned stock on Reddit's r/wallstreetbets.</p>\n<p>Traders also circulated a recent release from the Australian Government mentioning recognition of Bharat Biotech's COVAXIN. NOTE: Ocugen is a partner on COVAXIN.</p>\n<p>Ocugen's average session volume is 21.45 million over a 100-day period. </p>\n<p>Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125550592","content_text":"Ocugen stock jumped another 6% in premarket trading after soaring more than 18% yesterday amid heightened interest in the stock from retail traders on social media.\n\nAccording to SwaggyStocks, Ocugen was the fifth most mentioned stock on Reddit's r/wallstreetbets.\nTraders also circulated a recent release from the Australian Government mentioning recognition of Bharat Biotech's COVAXIN. NOTE: Ocugen is a partner on COVAXIN.\nOcugen's average session volume is 21.45 million over a 100-day period. \nOcugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6425463,"gmtCreate":1635857720358,"gmtModify":1635857720471,"authorId":3579777216498074,"author":{"id":3579777216498074,"idStr":"3579777216498074","authorId":3579777216498074,"name":"JANICELSJ","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":843733952,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"},{"id":843739555,"gmtCreate":1635857507399,"gmtModify":1635857507399,"author":{"id":"3578731486578016","authorId":"3578731486578016","name":"han1911","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3578731486578016","authorIdStr":"3578731486578016"},"htmlText":"To the moon","listText":"To the moon","text":"To the moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/843739555","repostId":1125550592,"repostType":4,"repost":{"id":"1125550592","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635857440,"share":"https://www.laohu8.com/m/news/1125550592?lang=&edition=full","pubTime":"2021-11-02 20:50","market":"us","language":"en","title":"Ocugen stock jumped another 6% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1125550592","media":"Tiger Newspress","summary":"Ocugen stock jumped another 6% in premarket trading after soaring more than 18% yesterday amid heigh","content":"<p>Ocugen stock jumped another 6% in premarket trading&nbsp;after&nbsp;soaring more than 18% yesterday&nbsp;amid heightened interest in the stock from retail traders on social media.</p>\n<p><img src=\"https://static.tigerbbs.com/c79efec1c07b47773449a998fa009813\" tg-width=\"847\" tg-height=\"619\" referrerpolicy=\"no-referrer\"></p>\n<p>According to SwaggyStocks, Ocugen was the fifth most mentioned stock on Reddit's r/wallstreetbets.</p>\n<p>Traders also circulated a recent release from the Australian Government mentioning recognition of Bharat Biotech's COVAXIN. NOTE: Ocugen is a partner on COVAXIN.</p>\n<p>Ocugen's average session volume is 21.45 million over a 100-day period. </p>\n<p>Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen stock jumped another 6% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen stock jumped another 6% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-02 20:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ocugen stock jumped another 6% in premarket trading&nbsp;after&nbsp;soaring more than 18% yesterday&nbsp;amid heightened interest in the stock from retail traders on social media.</p>\n<p><img src=\"https://static.tigerbbs.com/c79efec1c07b47773449a998fa009813\" tg-width=\"847\" tg-height=\"619\" referrerpolicy=\"no-referrer\"></p>\n<p>According to SwaggyStocks, Ocugen was the fifth most mentioned stock on Reddit's r/wallstreetbets.</p>\n<p>Traders also circulated a recent release from the Australian Government mentioning recognition of Bharat Biotech's COVAXIN. NOTE: Ocugen is a partner on COVAXIN.</p>\n<p>Ocugen's average session volume is 21.45 million over a 100-day period. </p>\n<p>Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125550592","content_text":"Ocugen stock jumped another 6% in premarket trading after soaring more than 18% yesterday amid heightened interest in the stock from retail traders on social media.\n\nAccording to SwaggyStocks, Ocugen was the fifth most mentioned stock on Reddit's r/wallstreetbets.\nTraders also circulated a recent release from the Australian Government mentioning recognition of Bharat Biotech's COVAXIN. NOTE: Ocugen is a partner on COVAXIN.\nOcugen's average session volume is 21.45 million over a 100-day period. \nOcugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6425909,"gmtCreate":1635860180379,"gmtModify":1635860180425,"authorId":4087129674670520,"author":{"id":4087129674670520,"idStr":"4087129674670520","authorId":4087129674670520,"name":"Shhui","avatar":"https://static.tigerbbs.com/a5f0d746b07cd5c1b600923db7d51578","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":843739555,"type":1,"supId":0,"prevId":0,"content":"Yea","text":"Yea","html":"Yea"},{"id":6425623,"gmtCreate":1635858477042,"gmtModify":1635858477162,"authorId":3577185043030916,"author":{"id":3577185043030916,"idStr":"3577185043030916","authorId":3577185043030916,"name":"Rontjk","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":843739555,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":67,"commentSize":5,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1125550592"}